XERS Insider Trading

Insider Ownership Percentage: 4.56%
Insider Buying (Last 12 Months): $10,155.45
Insider Selling (Last 12 Months): $217,200.00

Xeris Biopharma Insider Trading History Chart

This chart shows the insider buying and selling history at Xeris Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Xeris Biopharma Share Price & Price History

Current Price: $4.41
Price Change: Price Decrease of -0.47 (-9.63%)
As of 04/4/2025 05:00 PM ET

This chart shows the closing price history over time for XERS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$4.41Closing price on 04/05/25:

Xeris Biopharma Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Xeris Biopharma (NASDAQ:XERS)

42.75% of Xeris Biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at XERS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$27Mbought$31MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal InflowsTotal Outflows
Xeris Biopharma logo
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Read More on Xeris Biopharma

Today's Range

Now: $4.41
Low: $4.28
High: $4.73

50 Day Range

MA: $4.30
Low: $3.47
High: $5.87

52 Week Range

Now: $4.41
Low: $1.69
High: $6.07

Volume

3,865,163 shs

Average Volume

1,806,498 shs

Market Capitalization

$678.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Who are the company insiders with the largest holdings of Xeris Biopharma?

Xeris Biopharma's top insider investors include:
  1. Paul R Edick (Insider)
  2. John Patrick Shannon Jr (Insider)
  3. Beth Hecht (Insider)
  4. John P Schmid (Director)
  5. Jeffrey W Sherman (Director)
Learn More about top insider investors at Xeris Biopharma.